Volpara Health Technologies Ltd (ASX: VHT) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Volpara Health Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $171.37 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 252.02 million
Earnings per share -0.061
Dividend per share N/A
Year To Date Return -34.13%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Volpara Health Technologies Ltd (ASX: VHT)
Latest News

A woman holds her finger to the side of her lips in contemplation as she looks upwards to an array of graphic images of light bulbs above her head, one of which is on and glowing.

Here’s why I think these ASX shares are top ideas to buy right now

Some ASX shares may have been sold off too much.

Read more »

Four people on the beach leap high into the air.
Healthcare Shares

Volpara share price leaps 5% following record cash receipts

Volpara's results appeared to impress investors today.

Read more »

A young boy pushes his bicycle uphill on a rocky road. He is wearing a helmet and has his tongue hanging out as though he is making a face to show how exhausted he is.

Why I think these 2 ASX growth shares could keep marching upwards

Still down heavily in 2022, here are two ideas that I think could rebound.

Read more »

health workers shake hands and congratulate each other on good news
Share Gainers

This ASX All Ordindaries healthcare share is ripping 17% higher amid a new contract win

Investors seem to like the contract win from this healthcare player.

Read more »

happy investor, share price rise, increase, up
Growth Shares

Here’s where I’d invest $3,000 into ASX growth shares today

Some ASX growth shares are looking really good value, in my opinion.

Read more »

Dollar sign made from grass growing from ground as one person drips water on it and another holds coin
Growth Shares

2 ASX shares I think are great long-term buys

These two ASX shares have strong outlooks this decade. Here's why...

Read more »

ASX bank shares buy A young boy in a business suit giving thumbs up with piggy banks and coin piles
Share Market News

Could now be a great time to start investing in ASX shares?

Is it a good time to start investing in ASX shares? There has been a lot of volatility in 2022.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Earnings Results

Volpara share price up on record full-year results

ASX investors appear to be pleased with Volpara's results.

Read more »

VHT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Volpara Health Technologies Ltd

Volpara Health Technologies Ltd is a New Zealand-based research, development and manufacturing company. The company operates through the sale of a single suite of medical device software products. The business of the company operates through three product categories that include Capital Sales, Software Maintenance Agreement, and Software as a Service. Geographically the company exports its products to Asia Pacific, Europe, Middle East, Africa, USA, and Canada regions. The company's product consists of breast imaging analytics platform that delivers real-time quality assurance and performance monitoring. Volpara Health Technologies sells its product under the name of VolparaDensity, VolparaDose, VolparaServer, and VolparaAnalytics.

VHT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
10 Aug 2022 $0.67 $-0.01 -1.48% 157,684 $0.67 $0.69 $0.66
09 Aug 2022 $0.68 $-0.01 -1.46% 254,428 $0.68 $0.69 $0.67
08 Aug 2022 $0.69 $0.02 3.01% 145,075 $0.67 $0.69 $0.67
05 Aug 2022 $0.67 $0.02 3.08% 149,140 $0.65 $0.67 $0.64
04 Aug 2022 $0.65 $0.01 1.56% 385,985 $0.65 $0.70 $0.65
03 Aug 2022 $0.64 $0.00 0.00% 177,999 $0.64 $0.67 $0.64
02 Aug 2022 $0.64 $-0.03 -4.48% 358,481 $0.68 $0.70 $0.64
01 Aug 2022 $0.67 $-0.02 -2.92% 83,923 $0.69 $0.69 $0.67
29 Jul 2022 $0.69 $-0.01 -1.44% 282,184 $0.71 $0.71 $0.67
28 Jul 2022 $0.70 $0.05 7.75% 536,045 $0.71 $0.74 $0.65
27 Jul 2022 $0.65 $0.04 6.56% 137,587 $0.65 $0.66 $0.61
26 Jul 2022 $0.61 $-0.04 -6.15% 146,900 $0.65 $0.65 $0.61
25 Jul 2022 $0.65 $-0.02 -2.99% 315,885 $0.69 $0.69 $0.63
22 Jul 2022 $0.67 $0.03 4.65% 250,817 $0.68 $0.71 $0.67
21 Jul 2022 $0.65 $0.06 10.17% 443,215 $0.58 $0.65 $0.58
20 Jul 2022 $0.59 $0.04 7.34% 533,672 $0.56 $0.59 $0.56
19 Jul 2022 $0.55 $-0.01 -1.82% 58,881 $0.55 $0.56 $0.53
18 Jul 2022 $0.55 $0.03 5.77% 106,187 $0.53 $0.56 $0.53
15 Jul 2022 $0.52 $0.01 1.96% 205,792 $0.51 $0.53 $0.51
14 Jul 2022 $0.51 $0.02 4.08% 83,000 $0.49 $0.51 $0.49
13 Jul 2022 $0.49 $-0.03 -5.77% 189,040 $0.52 $0.52 $0.49
12 Jul 2022 $0.52 $-0.01 -1.90% 114,669 $0.52 $0.53 $0.51

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
29 Jun 2022 John Pavlidis Buy 69 $28,609
On-market trade.
22 Jun 2022 John Diddams Buy 30 $13,553
On-market trade.
16 Jun 2022 John Diddams Buy 30 $16,665
On-market trade.
15 Jun 2022 Paul Reid Buy 115 $66,958
On-market trade.
18 Aug 2021 Roger Allen Issued 150 $199,500
Issue of options. Considered Trade Qty from value consideration as Qty was not reported in number acquired.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr John Flower Diddams Non-Executive Director Oct 2015
Mr Diddams is the principal of an Australian CPA firm that provides companies with corporate advisory services. Mr Diddams has knowledge and practical experience in the application of Australian corporations law, ASX Listing Rules, international accounting standards, and corporate governance principles. Over the past 30 years, Mr Diddams has managed the processes to raise capital, perform due diligence, and seek ASX listing for a number of enterprises, including IPOs for a wide range of offerings. These include oil and gas interests, food and retail, a fine-wool processing plant, an innovative telephony product, a biotech company, an Internet advertising initiative, a dental device for snoring and sleep apnoea, an indoor skydiving company, the NZ developer of the Martin Jetpack, a healthy fast food chain, and Skydive the Beach Group Limited (now Experience Co Limited). Mr Diddams is currently a Non-Executive Director of Aroa Biosurgery Limited, an NZ-based company that develops and markets proprietary soft-tissue regenerative products; Surf Lakes Holdings Limited, a Gold Coast-based business with patented technology for recreational wave generation; and DIT AgTech Limited, a Queensland-based AgTech company focussed on nutrient supplementation for livestock, using Internet of Things technology to help farmers do more for less. Mr Diddams has recently been appointed Chairman and a Non-Executive Director of xReality Group Limited, a New South Wales company developing and operating physical and digital simulations. He is based in Sydney, Australia.
Mr Roger Allen Non-Executive DirectorNon-Executive Chairman Jun 2010
Mr Allen is an entrepreneur, venture capitalist, and social impact investor and philanthropist whose global career has spanned over 50 years. He helped pioneer the Australian technology industry through the Computer Power Group, one of the first Australian-founded tech companies to scale globally and subsequently IPO in 1987, turning over approx. $1B in today's currency. Following the company's acquisition in 1995, he cofounded Allen & Buckeridge Pty Ltd, one of the first early-stage VC firms. After helping establish two successor VC firms, Allen retired from the firm in 2007 and has since focused on his private VC portfolio of over 50 companies and his many social impact investments. He also established and funded a Public Benevolent Institute called Indigenous Capital Limited (ICL) to focus on indigenous economic development using best practise experience from the technology world. Roger has served on two Prime Ministers' Science and Technology Councils, chaired State Government ICT Advisory Boards, served as deputy Chairman of Austrade for seven years, and been an Adjunct Professor at Swinbourne University, UTS, and INSEAD school of Entrepreneurship in Paris & Singapore. Along with many prestigious industry accolades, in 2011 Allen was awarded the Order of Australia honour for services to IT, venture capital, and in recognition of his support of the Indigenous community and philanthropic sector.
Mr John Dimitrious Pavlidis Non-Executive Director Feb 2015
Mr Pavlidis has more than 30 years of experience as a senior healthcare executive, CEO, or company director in the areas of diagnostic imaging, women's health, image analysis and artificial intelligence, and cardiovascular therapies. From 2015 through 2019, Mr Pavlidis served as the President and CEO of Vytronus, Inc., a venture-backed startup using novel catheter-based ultrasound, machine learning, and robotics technology to treat atrial fibrillation, a cardiac arrhythmia. Prior to Vytronus, Mr Pavlidis was the President and CEO of Endoscopic Technologies, Inc., a leader in minimally invasive and endoscopic treatment of atrial fibrillation, until it was acquired by AtriCure, Inc. in 2014. Since 2007, Mr Pavlidis has also served on the board of directors of several health technology companies, including U-systems, Inc., which pioneered automated breast ultrasound imaging as an adjunct to mammography for breast cancer screening and was acquired by GE Healthcare in 2012. Previously, Mr Pavlidis served as President and CEO of R2 Technology, Inc., the pioneer and leader in computerassisted detection of breast cancer, until Hologic, Inc., acquired the company in 2006. Before joining R2 Technology, Mr Pavlidis was president of the global Ultrasound business at Siemens Healthcare, where he led the acquisition and integration of Acuson and subsequent growth of the combined organization to $1 billion in revenue. He shares his time between Europe and the USA.
Mr Paul Reid Non-Executive DirectorNon-Executive Chairman Mar 2018
Mr Reid brings commercial experience gained across a range of technology/Software as a Service (SaaS) businesses. He was the founding CEO and Chairman of Figured Limited, a fintech SaaS company that provides management accounting software to farmers in the USA, United Kingdom, Australia, and New Zealand ("NZ"). Figured was New Zealand's Startup of the Year in 2016 and has grown at an incredible pace, funded by private, corporate and venture capital (VC) investors. He is also currently CEO of Author-it Software Corporation, which provides documentation software for clinical, medical, and labelling information to Life Sciences companies in Europe and the United States of America (USA). Other key directorship roles include Christchurch International Airport Limited and Virsae Group Limited. Prior to embarking on a start-up and governance career, Mr Reid held a number of key executive roles, from CEO to COO, in businesses such as Air New Zealand, MetService, Carter Holt Harvey, and Ernst & Young.
Ms Karin Lindgren Non-Executive Director Jan 2020
Ms Lindgren joined the Board in 2020. She brings over 35 years' experience in health information technology as a senior technology executive and law firm partner. As one of the earliest healthcare technology lawyers in the US, Ms Lindgren has an in-depth knowledge of data governance, data privacy, SaaS, and US healthcare, and has extensive professional networks across the IT landscape. Her previous roles include General Counsel, Chief Compliance Officer & Chief Privacy Officer at the University Health System Consortium (which covers 90% of US academic medical centers); General Counsel & Chief Privacy Officer at ReedGroup, a data and informatics technology company responsible for absence management solutions at over 50 percent of Fortune 100 companies; and Senior VP, Legal Affairs, General Counsel, Corporate Secretary, Chief Compliance Officer, Chief Privacy Officer, and Chief Audit Executive at Availity, a revenue cycle management, electronic data interchange platform, PaaS IT company that operates the largest real-time information network in healthcare, connecting payers and providers in over seven billion transactions every year. Ms Lindgren was a founding faculty member in the Health Informatics Master's Programs at both Northwestern University (Chicago) and University of Colorado (College of Nursing), and has taught in schools of medicine, law, and business at numerous US universities. She is a board member of multiple private and non-profit organisations. Ms Lindgren is Chair of the Risk Committee and is based in Boulder, Colorado, USA.
Ms Ann Custin Non-Executive Director Sep 2021
Ms Custin brings a network of industry contacts from a career in healthcare across Europe, the Americas, and Asia. Her most recent executive role was with Siemens Healthineers, where she served as both CFO and board director of Siemens Medical Solutions. Prior to this role, Ms Custin served as Chief Operating and Financial Officer of Scient'x and President & CEO of USA Draeger Medical Systems, Inc. Ms Custin is also a Non-Executive Director of NASDAQ-listed Establishment Labs Holdings Inc., a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, that has a market capitalisation of approximately US$1.7 billion. Ms Custin recently became a board member of Mayne Pharma Group, a pharmaceutical company based in Australia that develops, manufactures, and markets branded and generic pharmaceutical products globally. Ms Custin is a member of the Audit Committee and is based in Bethlehem, Pennsylvania, USA.
Mr Craig Hadfield Chief Financial OfficerJoint Company Secretary Mar 2017
Ms Teri Thomas Chief Executive Officer Apr 2022
Teri Thomas Chief Executive Officer
Craig Hadfield Chief Financial OfficerJoint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 21,552,331 8.55%
Patagorang Pty Ltd 18,467,848 7.33%
Ralph Highnam And Kyc Trustees 106 Limited <Highnam Share A/C> 16,213,561 6.44%
Citicorp Nominees Pty Limited 11,668,974 4.63%
Custodial Services Limited <Beneficiaries Holding A/C> 8,570,155 3.40%
Prof Sir Michael Brady 6,619,075 2.63%
Mr Marcus Sarner 5,980,404 2.37%
National Nominees Limited 5,278,091 2.10%
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 4,239,652 1.68%
Hsbc Custody Nominees (Australia) Limited 4,043,265 1.60%
Sir Martin Francis Wood 3,004,655 1.19%
Lady Kathleen Audrey Wood 3,004,654 1.19%
Bnp Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 2,296,110 0.91%
Bnp Paribas Noms (Nz) Ltd <Drp> 2,221,506 0.88%
Prof Martin Yaffe 2,066,483 0.82%
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 1,903,048 0.76%
Prof Nico Karssemeijer 1,806,806 0.72%
Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C> 1,519,964 0.60%
Sir Martin Gregory Smith 1,366,977 0.54%
Mr John Anthony Dell 1,288,864 0.51%